Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenstrom Macroglobulinemia
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 14 Nov 2016 Status changed from suspended to discontinued because of the Safety issues from trials in CLL..
- 21 Mar 2016 Status changed from recruiting to suspended because of the pending safety review, according to ClinicalTrials.gov record.
- 27 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.